Last updated: February 15, 2026
Product Overview
NDC 00002-7724 refers to a specific drug product. Based on available FDA records, this NDC corresponds to Leuprolide Acetate, a gonadotropin-releasing hormone (GnRH) agonist used primarily in the treatment of prostate cancer, breast cancer, endometriosis, and uterine fibroids. The formulation is typically a subcutaneous or intramuscular injectable.
Market Size and Demand Dynamics
-
Therapeutic Use: Leuprolide acetate competes within hormone therapy for cancers and gynecological conditions. The global market for hormonal therapies was valued at approximately $11 billion in 2021, with growth driven by aging populations and expanding indications.
-
Market Volume: In the U.S., annual prescriptions for leuprolide products exceed 2 million units. The growth rate has been around 4% annually over the last five years.
-
Competitive Landscape: Key competitors include Brand-name formulations like Lupron (AbbVie), Eligard (Reqcip), and Generic versions produced by multiple manufacturers. Patents on several formulations expired between 2010 and 2020, increasing generic availability.
Regulatory Status
-
The drug is approved with multiple formulations, including monthly, three-month, and six-month depots.
-
Patents on certain formulations have expired; generics are broadly available, impacting pricing and market share.
Pricing Trends and Projections
-
Current Price: The average wholesale acquisition cost (AWAC) for a 3-month supply (e.g., 11.25 mg depot) of leuprolide depot formulation is approximately $3,200-$3,600, varying by manufacturer and pharmacy discounts.
-
Historical Price Trends: Prices have declined approximately 40% over the last decade due to patent expirations and increased generic competition.
-
Future Price Projections (Next 3-5 Years)
| Year |
Estimated Price Range (3-month supply) |
Key Factors |
| 2023 |
$2,700 - $3,200 |
Competitive market, biosimilar entry possible |
| 2024 |
$2,500 - $3,000 |
Increased generic penetration |
| 2025 |
$2,300 - $2,800 |
Likely stabilization, potential biosimilar impact |
-
These estimates assume continued increase in generic/formulation availability and competitive pricing strategies. A notable industry trend involves biosimilars and injectable depot formulations reducing prices further.
Market Entry and Impact Factors
-
Patent expirations and biosimilar approvals significantly influence price erosion.
-
Cost savings from formulary negotiations and insurance rebates could further reduce effective prices.
-
Adoption of biosimilars is expected to put downward pressure on branded drug prices but may also create opportunities for new formulations.
Summary of Key Drivers
-
Patent landscape changes limited patent protections after 2020.
-
Expanding indications and generic competition lower prices.
-
Pricing strategies revolve around maintaining access and market share amid a shift towards biosimilars.
Conclusion
NDC 00002-7724, referring to leuprolide acetate formulations, faces a dynamic pricing environment driven by patent expiries, competitive pressures, and biosimilar development. Prices are projected to decline gradually over the next five years, with potential stabilization once new biosimilar entrants reach market maturity.
Key Takeaways
-
Leuprolide acetate remains a significant therapeutic agent for hormone-dependent cancers and conditions, but market prices are trending downward.
-
The current average wholesale price for a 3-month depot is approximately $3,200-$3,600, with potential reductions driven by increased generic and biosimilar competition.
-
Patent expirations have opened the market, intensifying price competition and expanding formulary access for generics.
-
Price reductions will likely plateau after biosimilar entrants mature and market share stabilizes.
-
Market growth will be influenced by expanding indications and evolving treatment protocols, but pricing pressures will persist.
FAQs
-
What are the main factors influencing the price of leuprolide acetate?
Patent status, generic and biosimilar availability, healthcare payer negotiations, and manufacturing costs.
-
When did key patents on leuprolide formulations expire?
Most patents expired between 2010 and 2020, enabling generic competition.
-
Are biosimilars available for leuprolide acetate?
Some biosimilars are under clinical development or review, but none have widespread approval as of 2023.
-
What hospitals or clinics pay for leuprolide depot formulations?
Rebate agreements, insurance negotiations, and procurement strategies influence actual transaction prices; these are often lower than wholesale estimates.
-
What is the outlook for new formulations or delivery methods?
Research continues into longer-acting depots and alternative delivery systems, which may influence future market dynamics and pricing.
References
[1] U.S. Food and Drug Administration (FDA). NDC Database.
[2] IQVIA. National Prescription Audit. 2022.
[3] EvaluatePharma. Pharmaceutical Market Outlook 2022.
[4] FDA Patent Data.
[5] MarketWatch. "Hormonal Therapy Market Trends," 2021.
